ArticleJournal of inflammation research2026
APOA4 Protects Chondrocytes and Modulates Wnt Signaling in Osteoarthritis.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteoarthritis (OA) pathogenesis involves dysregulated extracellular matrix (ECM) remodeling and inflammation. Apolipoprotein A4 (APOA4), while known for lipid metabolism, has an uncharacterized role in OA. Methods: Clinical samples including infrapatellar fat pad (IFP) (n=3), synovial fluid (n=11), and serum (n=11) from patients with and without OA were analyzed via immunohistochemistry (IHC) and ELISA. In vitro, human chondrocytes (C28/I2) were treated with recombinant APOA4 (5 nM), siRNA knockdown (si-APOA4), or overexpression (OE-APOA4). Functional assays (qPCR, RNA-seq, CCK-8, colony formation) and inflammatory modeling (IL-1β ± APOA4) assessed chondrocyte responses. Wnt pathway involvement was probed via Wnt3a rescue. Results: APOA4 expression was significantly elevated in OA IFP tissues, synovial fluid, and serum vs. controls (p < 0.05). APOA4 treatment upregulated the level of anabolic markers (COL2, p=0.0006; ACAN p=0.0055) and downregulated catabolic factors (MMP3, p=0.0249; MMP13, p=0.0214), while enhancing chondrocyte proliferation. OE-APOA4 mimicked these effects, whereas si-APOA4 reversed them. APOA4 attenuated IL-1β-induced inflammation, preserving COL2/ACAN and suppressing MMPs. RNA-seq implicated Wnt/β-catenin suppression (NES = -1.314; p = 0.008) as a key mechanism. Wnt3a treatment partially reversed APOA4's chondroprotective effects. Conclusion: APOA4 mitigates OA progression by promoting ECM anabolism, inhibiting inflammation, and suppressing Wnt/β-catenin signaling. It represents a novel therapeutic target for OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.